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Abstract 
Objective: Renal outcomes after critical illness are seldom assessed, despite strong 
correlation between chronic kidney disease (CKD) and survival. Outside hospital, 
renal dysfunction is more strongly associated with mortality when assessed by serum 
cystatin-c than by creatinine. The relationship between creatinine and longer-term 
mortality might be particularly weak in survivors of critical illness.  
  
Design: Retrospective observational cohort study 
  
Patients: In 3077 adult intensive care unit (ICU) survivors we compared ICU-
discharge cystatin-c and creatinine and their association with one year mortality. 





Measurements and main results: During ICU admission serum cystatin-c and 
creatinine diverged so that by ICU discharge, almost twice as many patients had 
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glomerular filtration rate (GFR) <60ml/min/1.73m2 when estimated from cystatin-c 
(eGFR-Cys-c) compared to creatinine (eGFR-Cr), 44% vs. 26%. In 743 patients 
without AKI, where ICU-discharge renal function should reflect ongoing baseline, 
discharge eGFR-Cr consistently over-estimated follow-up eGFR-Cr, while ICU-
discharge eGFR-Cys-c well-matched follow-up CKD status.  By one year 535 
(17.4%) had died. In survival analysis adjusted for age, sex and comorbidity, cystatin-
c was near-linearly associated with increased mortality, hazard ratio (HR)=1.78 (95% 
CI: 1.46-2.18), 75th versus 25th centile. Conversely, creatinine demonstrated a J-
shaped relationship with mortality, so that in the majority of patients there was no 
significant association with survival, HR=1.03 (0.87-1.2), 75th vs. 25th centile. After 
adjustment for both creatinine and cystatin-c levels, higher discharge creatinine was 
then associated with lower long-term mortality. 
  
Conclusions: In contrast to creatinine, cystatin-c consistently associated with long-
term mortality, identifying patients at both high and low risk, and better correlated with 
follow-up renal function. Conversely, lower creatinine relative to cystatin-c appeared 
to confer adverse prognosis, confounding creatinine interpretation in isolation. 
Cystatin-c warrants further investigation as a more meaningful measure of renal 




Acute kidney injury (AKI) increases risk of development or progression of chronic 
kidney disease (CKD) after critical illness(1, 2). CKD is associated with long-term risk 
of cardiovascular morbidity, end-stage renal disease (ESRD) and short- and long-
term risk of death(3-6). Despite these important associations, survivors of critical 
illness with AKI rarely receive nephrology follow-up(7). 
Assessment of renal function in survivors of critical illness requires tests of renal 
function that accurately reflect risk of long-term adverse outcomes. The endogenous 
biomarkers of renal function, creatinine and cystatin-c, both indirectly assess 
glomerular filtration rate (GFR)(8). While creatinine is standard, cystatin-c has limited 
uptake worldwide, despite potential superiority in prognostication of patients with 
CKD(9). Furthermore, interpretation of serum creatinine in intensive care survivors 
may be confounded by decreased creatinine generation(10, 11), thought to be a 
consequence sustained muscle wasting observed in critical illness.  This effect is 
doubly confounding as muscle wasting is itself associated with adverse patient 
outcomes(12).  
Cystatin-c is produced in nucleated cells and less confounded by acute and chronic 
illness, changes in diet and decreased muscle mass(13). In patients with CKD, 
estimated GFR (eGFR) based on cystatin-c better predicts mortality than eGFR 
based on creatinine which demonstrates a J-shaped relationship with risk of death(9). 
However, the relationship between cystatin-c and longer-term survival has not been 
compared to that of creatinine in the critically ill. 
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Accordingly, we examined seven years of patient data from a major teaching hospital 
intensive care unit (ICU) where both serum creatinine and cystatin-c are routinely 
measured. We hypothesized that, as a more accurate reflection of underlying renal 
function, cystatin-c would be strongly associated with long-term risk of death after 
ICU-discharge while serum creatinine might perform comparatively poorly.  
 
Materials and methods 
Study design 
This cohort study was conducted in the multidisciplinary ICU at the Karolinska 
University Hospital Solna, Sweden: a 13-bed unit with approximately 1000 
admissions yearly. The Stockholm Regional Ethics Committee approved the study, 
waiving informed consent due to retrospective observational nature of the study. 
 
Inclusion and exclusion criteria 
We screened all ICU patients admitted between October 2006 and December 2013. 
During this period, we only considered a patient’s first ICU-admissions of >24h. We 
excluded deaths in-ICU or within three days of ICU-discharge, patients lacking 
linkage to mortality data, any patients with ESRD prior to ICU-admission or new 
ESRD with a chronic dialysis commencement date within 14 days of ICU-discharge. 
Lastly, we excluded patients lacking cystatin-c measurement near ICU-discharge (up 




Cystatin-c was determined with a turbidimetric method (Gentian Cystatin-c UDR-Kit 
for Beckman-Coulter Synchron and UniCel Systems, Ref A52761). Creatinine was 
determined with a modified Jaffe method (CREm, Creatinin, Ref 472525). We 
calculated eGFR for both markers using CKD-EPI(14).   
 
Data collection 
Patients were monitored using the patient database management system Clinisoft® 
GE, USA. From hospital electronic health records (EHR), (Take Care®, CompuGroup 
Medical, Germany) we linked diagnosis data from the index admission and prior 
clinical encounters with ICD-10 coding for assessment of comorbidities and 
calculation of Charlson Comorbidity Index, Quan modification (CCI)(15, 16). Linkage 
to EHR laboratory information before and after ICU-admission allowed assessment of 
pre-morbid, hospital discharge and follow-up creatinine. AKI was defined by the 
KDIGO criteria(17) as a 1.5 fold increase in serum creatinine from baseline during 
ICU-admission or an absolute 0.3mg/dl increase over a ≤48h period. Baseline 
creatinine was defined as the last value from 365 days to 7 days prior to hospital 
admission, or if unavailable the value closest to the admission value. Follow-up 
creatinine was the most recent value available from 30 days to one year after hospital 
discharge. Swedish resident registration number (18) allowed identification of date of 
all deaths. Linkage with the Swedish Renal Registry (SRR) allowed identification of 




Statistical analysis was performed using R Development Core Team R Foundation 
for Statistical Computing, Vienna, Austria, http://www.R-project.org using the 
packages Survival, SmoothHR, icd and rms. Continuous variables are presented as 
median with interquartile range. Univariable comparisons were performed using the 
Wilcoxon Rank Sum Test, the Wilcoxon Signed-Rank Test and Fisher’s Exact Test 
for continuous, paired continuous and binary data.  Unadjusted survival data was 
stratified by quartiles of creatinine or cystatin-c and plotted as a Kaplan-Meier 
estimator and compared using the log-rank test. A two-tailed p-value of <0.05 was 
considered statistically significant.   
 
Multivariable modelling 
To assess the independent effect of renal filtration markers on survival in the year 
after hospital discharge multi-variable Cox proportional-hazard survival models were 
developed. To avoid concern regarding accuracy of eGFR equations in the ICU 
population we modeled the relationship between absolute creatinine or cystatin-c and 
mortality. We included age, sex, and comorbidity as covariates in our multivariable 
survival model as baseline factors likely to be associated with post ICU-survival 
and/or with renal function. In previous analyses of ICU survivors, comorbidity index 
was a stronger predictor of long term mortality than ICU-admission severity scoring 
(calibrated to short term risk of death)(19). To best illustrate the influence of AKI on 
the association of the filtration markers on survival we repeated analyses considering 
only AKI or non-AKI patients.  In all models, we tested the proportional-hazards 
assumption by correlating the corresponding set of scaled Schoenfeld residuals with 
a Kaplan-Meier estimate of the survival function and non-proportional covariates 
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were handled by stratification for that variable.  Based on general population data we 
hypothesized that creatinine or cystatin-c would be non-linearly related to risk of 
death; accordingly, these variables were fitted to a penalized spline. The degree of 
curve smoothing in the final model was determined by an algorithm based on 
minimization of Akaike’s Information Criterion (AIC). Finally, we included creatinine 
and cystatin-c in a single age, sex and comorbidity adjusted multivariable model to 




After exclusions, 3077 survivors were included for primary analysis (Supplement 
Figure S1). By 90 days after ICU-discharge 318 died (10.3%) rising to 536 (17.4%) at 
one year.  Nine patients developed new ESRD in the year after ICU-discharge. Non-
survivors were older, had greater comorbidity, higher SAPS3 score, more often 
developed AKI and required RRT.  Patients dying in the year after ICU-discharge had 
higher admission, peak and ICU-discharge creatinine than long-term survivors but 
these differences were more marked for cystatin-c at all time-points (Table 1). 
Importantly, while creatinine fell, from ICU-admission to discharge, cystatin-c rose 
over the same period (Table 1).  
 
Renal function markers and mortality after ICU-discharge 
Cystatin-c and creatinine at ICU-discharge differed distinctly in their association with 
mortality over the next 90 and 365 days (Table 2). The lowest cystatin-c quartile 
defined a low-risk population with a 5.6% one year mortality, compared to 13.6% in 
the lowest creatinine quartile. Overall, rates of death were well separated with 
increasing rates of death between quartiles of discharge cystatin-c whilst for 
creatinine only the upper quartile was separated (Figure 1).  
 
Multi-variable survival analysis 
To detect non-linear relationship between filtration markers and mortality risk, 
creatinine and cystatin-c were fitted to penalized splines in a multivariable survival 
model including sex, stratified for age and comorbidity index. Increasing cystatin-c 
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was near-linearly related to increasing HR for death; conversely creatinine 
demonstrated a J-shaped relationship (Figure 2). These relationships persisted when 
patients with or without AKI were considered separately (Figure S2). Considering 
both creatinine and cystatin-c together in a new multivariable model including age 
sex and comorbidity, increasing cystatin-c remained strongly associated with 
increasing HR for death, however, higher creatinine was then associated with lower 
hazard of death at all creatinine levels (Figure 3). 
 
Relationship between cystatin-c and creatinine based estimates of GFR 
Median eGFR at ICU-discharge based on creatinine was greater than using cystatin-
c (92 vs. 68ml/min/1.73m2, p<0.001). Using cystatin-c for eGFR identified 1362 
(44%) patients <60ml/min/1.73m2 at ICU-discharge compared to only 794 (26%) 
using creatinine based eGFR. Despite a substantially larger population with low 
eGFR, there was similar mortality in the cystatin-c group with eGFR<60 compared to 
that defined by creatinine eGFR (cystatin-c: 386/1362, 28% vs. creatinine: 233/794, 
29%, (Table S1).  
 
We examined cystatin-c/creatinine divergence during ICU-stay by comparing ratio of 
creatinine to cystatin-c eGFR for different durations of ICU-admission (Figure S3).  In 
admissions lasting 1-2 days, the median ratio was 1.01 (IQR: 0.87-1.24). However, 
with longer admissions eGFR by creatinine was consistently greater than eGFR 
cystatin-c. For ICU-admissions of >20 days values of eGFR (creatinine) were a 
median of 2.1 (IQR 1.7-2.8) fold greater than corresponding eGFR (cystatin-c). 
Finally, to illustrate the timing of changes in creatinine and cystatin-c after ICU 
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admission we examined changes in creatinine, cystatin-c and C-reactive protein 
(CRP) over the first seven days of ICU admission and at ICU discharge in a subset of 
516 patients with ICU admissions of ≥7 days. In this analysis creatinine progressively 
fell while at the same time cystatin-c rose (Fig S4). During this period, CRP had a 
biphasic profile and did not correlate with the two endogenous renal filtration 
markers. 
 
To explore the discrepancy of cystatin-c and creatinine at ICU-discharge we 
considered 743 patients without AKI in the ICU (where ICU-discharge renal function 
would be expected to be similar to follow-up) who had a creatinine measurement in 
the 30-365 days after discharge and survived to 1 year.  In this group, we compared 
cystatin-c and creatinine eGFR at ICU-discharge against follow-up creatinine eGFR 
(at a median of 267 days (IQR 145-334) after hospital discharge). GFR based on 
cystatin-c better agreed with CKD categorization at follow-up, particularly in the GFR 
range 30-60. In contrast, discharge creatinine eGFR over-estimated follow-up GFR in 
all CKD categories (Figure S5, Table S2). 
 
Discussion 
Interpretation of findings 
In a large critically ill adult patient population we found cystatin-c was near linearly 
associated with age and comorbidity-adjusted 90- and 365-day mortality. In contrast, 
creatinine was unable to discriminate low-risk patients, showing a flattened J-shaped 
relationship with risk of death. While in the majority of patients discharge creatinine 
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that was not significantly predictive of risk of death, across the full range of measured 
values, cystatin-c provided prognostic information. 
 
In line with these findings, during ICU-admission on average creatinine fell, while in 
the same patient group cystatin-c rose, resulting in a striking 24ml/min/1.73m2 
median difference in eGFR based on cystatin-c vs. creatinine at ICU-discharge. Both 
markers supposedly reflect true underlying GFR, but clearly one, or both, fail to do so 
in this setting. If excretion of markers is similarly affected by renal function, the 
generation rate of one or both must be substantially altered during critical illness. 
Given that cystatin-c is robustly related to risk of death while creatinine is not, we 
believe our findings are most compatible with cystatin-c better reflecting underlying 
renal function. This conclusion is supported by the observation that, in non-AKI-
patients, where underlying GFR would not be expected to change markedly during 
convalescence, ICU-discharge cystatin-c eGFR better correlated with follow-up CKD-
status than creatinine eGFR (Figure S4, Table S2). 
 
Acute and chronic reduction in creatinine generation with muscle wasting may 
explain an inability to associate lower discharge creatinine with better prognosis, an 
interpretation strengthened by the finding that, for short ICU-admissions, cystatin-c 
and creatinine eGFR at discharge are similar. With longer ICU stays eGFR 
(creatinine) tends to be increasingly higher than eGFR (cystatin-c), a finding 
compatible with progressive muscle wasting during prolonged critical illness (Figure 
S3). Finally, when both markers were considered together in a survival model, 
increasing cystatin-c remained strongly associated with mortality, however, 
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increasing creatinine then became consistently associated with lower mortality, 
potentially reflecting lower mortality in patients with less muscle wasting (Figure 3). 
 
Relation to previous studies 
Assessment of renal function using creatinine has been shown to be confounded by 
progressive creatinine reduction associated with critical illness(10, 11) and 
accounting for these reductions results in more than doubling of patients with 
potential CKD at ICU-discharge. Decreased creatinine excretion, paralleling 
decreased production has been demonstrated with prolonged critical illness(11). In 
contrast, several studies suggest that cystatin-c outperforms creatinine in ICU 
populations. In cardiovascular surgery, creatinine eGFR over-estimated iohexol 
measured-GFR whereas cystatin-c eGFR well-matched(20). Similarly, in a general 
ICU patients, cystatin-c-estimated GFR was significantly lower than creatinine 
eGFR(21). Reductions in creatinine generation have been demonstrated in an animal 
model of sepsis(22); notably, in this model cystatin-c production was not 
increased(23), suggesting any cystatin-c elevation during critical illness is likely to 
reflect reduced renal clearance. The hypothesis that cystatin c production rises as an 
inflammatory response has also not been supported by previous comparisons to 
inflammatory markers in humans(24), while, in our study, elevation in cystatin-c was 
progressive and persistent, despite resolution of systemic inflammation as indicated 
by fall in CRP (Fig S4). 
 
We have previously demonstrated an association between cystatin-c but not 
creatinine short term ICU mortality in a small sample of patients(25). This study 
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extends those findings, demonstrating a consistent association between cystatin-c at 
ICU-discharge and longer-term mortality in a much larger population critically ill 
patients with and without AKI. Cystatin-c has also been shown to better-correlate with 
mortality in settings where creatinine values may be confounded by premorbid 
condition, including vascular surgery patients(26), HIV patients(27), liver transplant 
recipients(28) and in acute heart failure(29); as well as in the general population and 
patients with CKD(9).  
 
Study Implications 
Consequences of AKI include increased long-term risk of death, cardiovascular 
events, development of CKD, and ESRD(5, 6). Incomplete recovery from severe AKI 
is a well-recognized pathway to persistent and progressive CKD (30), but recent 
studies suggest that apparently completely recovered AKI remains associated with a 
subsequent risk of CKD and death(5, 31). Importantly, the majority of such patients 
do not receive kidney-directed follow-up. Our findings suggest that a substantial 
number of these patients could have significant renal dysfunction undetected by 
creatinine. Notably, in this study, the where ICU-discharge renal function would be 
expected to be similar to follow-up 628 “extra” patients identified with an ICU-
discharge eGFR of <60 by cystatin-c, but not creatinine, had similar risk of death to 
patients with eGFR <60 by creatinine based calculation, suggesting cystatin is 
correctly classifying patients at increased risk. Cystatin-c has the potential to target a 
larger group of high-risk patients for specialist follow-up that might improve 
outcomes(32) and also to accurately identify a group of low risk patients.   
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Strengths and weaknesses 
This study is the largest comparison between creatinine and cystatin-c as markers of 
renal function in ICU patients. High-resolution data-linkage allowed us to precisely 
identify the presence and severity of AKI in the ICU, to collect detailed comorbidity 
data, to remove chronic dialysis patients and to obtain accurate all-cause mortality 
(33).  
 
A weakness of this study is lack of gold standard GFR. Despite circumstantial 
evidence that our results reflect limitations of serum creatinine as a GFR biomarker 
after critical illness, without reliable measurement of GFR we cannot exclude the 
presence of increased cystatin-c production that is independently associated with 
increased mortality(9, 34). However, evidence suggests that such increases are not 
observed in clinical or experimental sepsis(23, 35).  Cystatin-c measurements were 
confined to the ICU, i.e. the time-point of comparison, at ICU-discharge, was one of 
only relative clinical stability and renal recovery after AKI may still be occurring at this 
point. Our primary analysis concentrated on absolute values of creatinine and 
cystatin-c. To compare predicted renal function from these markers we used eGFR in 
secondary analyses, eGFR equations are unlikely to be accurate in the critically ill, 
however the purpose of such comparison is only to better-demonstrate the 
discrepancy between the markers and their agreement with baseline and follow-up.  
Finally, being a single center study, our findings would need confirmation in groups of 




In a large population of critically ill patients, cystatin-c progressively rose during ICU 
treatment while creatinine fell, despite both being markers of glomerular filtration. 
Levels of cystatin-c after critical illness were strongly associated with 90-day and 
one-year mortality both in AKI- and non-AKI-patients.  Cystatin-c identified almost 
twice as many patients as having clinically significant renal dysfunction at ICU-
discharge and was superior in CKD categorization in the year following the critical 
illness. Conversely, creatinine was poorly related to risk of death and, in isolation, 
had little value as a prognostic marker in the majority of patients. Cystatin-c is likely 
to be the superior renal functional marker in survivors of major illness and should be 
investigated as a prognostic marker for patients at risk of CKD for follow-up and 
targeted intervention. 
 
Figure 1. Crude mortality in the year after ICU-discharge stratified by quartiles of Creatinine 
or Cystatin-c at ICU-discharge. 
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Figure 2. Age and Sex adjusted Hazard Ratios for survival in the year after ICU-discharge 
fitted with penalized spline regression for ICU-discharge Creatinine and Cystatin-c. Stratified 
Cox-Model (Strata: Co-morbidity Index category (0, 1-2, 3-4, 5-6, >6) and octiles of age). 
Values plotted from the 5th to 95th centiles the predictor variable and distribution of values 
within this range is marked above the x-axis. Reference is 25th centile value set to HR=1, 
25th, 50th & 75% centiles are marked with vertical lines.   
 
 18 
Figure 3. Including Cystatin-c and Creatinine together in a single Cox-Proportional Hazard 
survival model, Age and Sex adjusted Hazard Ratios for survival in the year after ICU-
discharge fitted with penalized spline regression for ICU-discharge Creatinine adjusted for 
Cystatin-c and Cystatin-c adjusted for Creatinine. Stratified Cox-Model (Strata: Co-morbidity 
Index category (0, 1-2, 3-4, 5-6, >6) and octiles of age). Values plotted from the 5th to 95th 
centiles the predictor variable and distribution of values within this range is marked above the 
x-axis. Reference is 25th centile value set to HR=1, 25th, 50th & 75% centiles are marked with 




Table 1. Demographics and renal filtration markers in concentrations in survivors and non-
survivors 













Number! 3077! 100%! 2542! 82.6%! 535! 17.4%!
Age! 59! 41.70! 56! 38.68! 69! 60.76!
Male!Sex! 1899! 61.7%! 1559! 61.3%! 340! 63.4%!
ICU!LOS!(h)! 58! 34.120! 58! 33.119! 62! 37.125!
SAPSF3*! 37! 26.50! 35! 24.48! 47! 36.57!
Medical 1348 43.8% 1039 40.9% 309 57.8% 
Surgical 959 31.2% 776 30.5% 183 34.2% 












1.01! 0.75.1.53! 0.94! 0.72.1.38! 1.36! 1.02.1.93!
Peak!
Creatinine!
1.06! 0.79.1.66! 1.03! 0.77.1.56! 1.30! 0.87.2.15!
Peak!
CystatinFc!
1.20! 0.83.1.93! 1.11! 0.80.1.76! 1.69! 1.19.2.52!
Discharge!
Creatinine! 0.83! 0.63.1.20! 0.80! 0.62.1.13! 1.02! 0.69.1.57!
Discharge!
CystatinFc!
1.10! 0.80.1.63! 1.01! 0.77.1.48! 1.57! 1.12.2.16!
Discharge!
eGFR!(Cre)!
92! 58.112! 95! 65.115! 70! 41.96!
Discharge!
eGFR!(CysFc)!
68! 37.105! 76! 44.109! 40! 26.64!
RRT!in!ICU! 238! 7.7%! 177! 7.0%! 61! 11.4%!
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Table 2. Crude mortality and adjusted hazard ratios for death over 90day and one year 











Q1! Q2! Q3! Q4!
Cystatin-c!
Values*(mg/L)! 0.20%0.80! 0.80%1.10! 1.10%1.63! 1.63%8.48! 1.63!vs.!0.80!
90-day!
mortality!











0.1%0.63! 0.63%0.83! 0.83%1.20! 1.20%11.55! 1.20!vs.!0.63!
90-day!
mortality!
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